

**Table S5.** Summary statistics for associations<sup>a</sup> with risk of follicular lymphoma in Stages 1 and 2 with combined *P*-values. SNPs in bold were taken forward to Stage 3. The closest gene within 50Kb is shown.

Chromosomal location	SNP	Gene	Position	Minor /major	SCALE1			SF			Combined	
					MAF Controls	OR(95% CI)	P-value	MAF Controls	OR (95% CI)	P-value	OR (95% CI)	P-value
rs2647012	<b>6p21.32</b>	<i>HLA-DQB1</i>	32772436	allele A/G	<b>0.44</b>	<b>0.61 (0.51-0.73)</b>	<b>1.10E-07</b>	<b>0.36</b>	<b>0.64 (0.47-0.86)</b>	<b>4.77E-03<sup>b</sup></b>	<b>0.62 (0.53-0.72)</b>	<b>1.64E-09</b>
rs6932542	6p21.32	<i>BTNL2</i>	32488240	A/G	0.5	0.63 (0.53-0.75)	2.33E-07	0.48	0.64 (0.46-0.88)	1.70E-02 <sup>b</sup>	0.63 (0.54-0.74)	5.30E-09
rs9275572	6p21.32	<i>HLA-DQA2</i>	32786977	A/G	0.48	0.64 (0.53-0.76)	7.30E-07	0.39	0.59 (0.44-0.81)	5.52E-04 <sup>b</sup>	0.62 (0.54-0.73)	2.09E-09
<b>rs6536942</b>	<b>4q32.3</b>	<i>TLL1</i>	<b>167205644</b>	G/A	<b>0.12</b>	<b>1.80 (1.42-2.29)</b>	<b>1.14E-06</b>	-	-	-	-	-
<b>rs716183</b>	<b>10q25.3</b>	<i>VAX1</i>	<b>118894485</b>	C/T	<b>0.36</b>	<b>1.56 (1.30-1.86)</b>	<b>1.59E-06</b>	<b>0.42</b>	<b>1.16 (0.84-1.62)</b>	<b>0.42</b>	<b>1.46 (1.25-1.70)</b>	<b>1.88E-06</b>
rs504985	6q25.1	<i>TAB2</i>	149700671	G/T	0.36	1.52 (1.27-1.81)	3.80E-06	0.4	1.12 (0.81-1.56)	0.47	1.42 (1.21-1.65)	1.10E-05
rs11819305	10q25.3	<i>VAX1</i>	118898040	A/G	0.31	1.52 (1.27-1.83)	1.03E-05	0.36	1.04 (0.76-1.42)	0.8	1.38 (1.18-1.62)	4.68E-05
rs1912822	4q32.3	<i>MARCH1</i>	164744059	A/G	0.34	1.49 (1.25-1.78)	1.03E-05	0.36	1.18 (0.86-1.62)	0.44	1.41 (1.21-1.64)	1.44E-05
rs1860373	17q23.2	<i>BCAS3</i>	56643678	C/T	0.16	1.61 (1.30-2.00)	1.16E-05	0.15	1.00 (0.71-1.41)	0.94	1.41 (1.18-1.69)	2.00E-04
rs2868145	19q13.3	<i>PDCD5</i>	37738954	G/A	0.14	1.66 (1.33-2.08)	1.24E-05	0.15	1.24 (0.89-1.72)	0.29	1.51 (1.26-1.82)	1.21E-05
rs2179367	6q25.1	<i>ZC3H12D</i>	149804230	C/T	0.37	1.48 (1.24-1.76)	1.37E-05	0.41	1.15 (0.83-1.60)	0.42	1.40 (1.20-1.63)	2.24E-05
rs7453920	6p21.32	<i>HLA-DQB2</i>	32837990	A/G	0.5	0.69 (0.58-0.82)	1.83E-05	0.41	0.72 (0.53-0.99)	5.90E-02	0.70 (0.60-0.81)	4.40E-06
rs2301271	6p21.32	<i>HLA-DQB2</i>	32833171	T/C	0.5	0.69 (0.58-0.82)	1.91E-05	0.41	0.72 (0.53-0.99)	5.50E-02	0.70 (0.60-0.82)	4.21E-06
rs3817973	6p21.32	<i>BTNL2</i>	32469089	A/G	0.42	1.46 (1.22-1.74)	1.94E-05	0.42	1.08 (0.78-1.50)	0.12	1.36 (1.17-1.59)	7.30E-05
rs4424066	6p21.32	<i>BTNL2</i>	32462406	G/A	0.42	1.46 (1.22-1.73)	2.21E-05	0.42	1.08 (0.78-1.51)	0.12	1.36 (1.17-1.59)	7.67E-05
rs10484561	6p21.32	<i>HLA-DQB1</i>	32773398	G/T	0.11	1.72 (1.34-2.19)	2.33E-05	0.13	2.06 (1.48-2.85)	2.67E-05 <sup>b</sup>	1.83 (1.51-2.23)	1.25E-09
rs2051549	6p21.32	<i>HLA-DQB2</i>	32838064	C/T	0.5	0.70 (0.58-0.83)	2.42E-05	0.41	0.74 (0.54-1.02)	7.50E-02	0.71 (0.61-0.82)	8.30E-06
rs6457617	6p21.32	<i>HLA-DQB1</i>	32771829	C/T	0.51	0.68 (0.58-0.82)	2.64E-05	0.49	0.60 (0.44-0.83)	1.28E-03 <sup>b</sup>	0.66 (0.57-0.78)	2.02E-07
rs13209234	6p21.32	<i>HLA-DRA</i>	32523953	A/G	0.14	1.62 (1.29-2.03)	3.10E-05	-	-	-	-	-
rs4447756	3p14.2	<i>PTPRG</i>	61939996	C/A	0.44	0.68 (0.57-0.82)	3.23E-05	0.4	0.94 (0.68-1.29)	0.55	0.74 (0.63-0.86)	1.50E-04
rs2076530	6p21.32	<i>BTNL2</i>	32471794	G/A	0.43	1.44 (1.21-1.72)	3.28E-05	0.42	1.13 (0.81-1.58)	9.60E-02	1.37 (1.17-1.60)	6.68E-05
rs2858331	6p21.32	<i>HLA-DQA2</i>	32789255	C/T	0.3	1.46 (1.22-1.75)	3.30E-05	0.42	1.60 (1.14-2.28)	2.00E-04 <sup>b</sup>	1.49 (1.27-1.75)	1.27E-06
rs934320	10q26.12	<i>WDR11</i>	122694003	T/C	0.47	0.68 (0.57-0.82)	3.34E-05	0.45	0.93 (0.67-1.30)	0.89	0.73 (0.63-0.86)	9.43E-05
rs6477205	9p24.1	-	7506770	T/G	0.35	1.45 (1.21-1.73)	3.67E-05	0.35	1.17 (0.86-1.60)	0.92	1.38 (1.18-1.60)	5.13E-05
rs1015735	18q12.3	-	39877321	C/T	0.26	1.48 (1.23-1.80)	3.84E-05	0.31	1.00 (0.74-1.37)	0.99	1.34 (1.14-1.57)	4.50E-04

rs4340393	18q12.3	-	39884052	T/C	0.25	1.48 (1.23-1.79)	4.03E-05	0.31	1.00 (0.74-1.36)	0.95	1.33 (1.13-1.56)	5.10E-04
rs1386706	13q31.1	-	82314548	A/G	0.04	2.21 (1.53-3.19)	4.06E-05	0.06	1.17 (0.74-1.81)	0.34	1.71 (1.29-2.27)	2.10E-04
rs9498335	6q25.1	<i>TAB2</i>	149735477	A/C	0.26	1.48 (1.23-1.79)	4.18E-05	0.29	0.99 (0.73-1.34)	0.72	1.32 (1.13-1.56)	5.80E-04
rs10214840	6q25.1	<i>TAB2</i>	149685402	C/T	0.26	1.48 (1.22-1.79)	4.35E-05	0.29	0.99 (0.73-1.35)	0.71	1.32 (1.13-1.56)	5.78E-04
<b>rs9277554</b>	<b>6p21.32</b>	<b><i>HLA-DPB1</i></b>	<b>33163516</b>	<b>T/C</b>	<b>0.28</b>	<b>0.64 (0.52-0.79)</b>	<b>4.53E-05</b>	<b>0.29</b>	<b>0.76 (0.55-1.03)</b>	<b>9.79E-02</b>	<b>0.67 (0.57-0.80)</b>	<b>7.39E-06</b>
<b>rs441890</b>	<b>8q13.3</b>	<b><i>LACTB2</i></b>	<b>71727221</b>	<b>G/A</b>	<b>0.4</b>	<b>1.44 (1.21-1.72)</b>	<b>6.80E-05</b>	<b>0.42</b>	<b>1.42 (1.02-2.02)</b>	<b>4.71E-03<sup>b</sup></b>	<b>1.44 (1.23-1.68)</b>	<b>4.91E-06</b>
rs4567602	13q31.1	-	8299724	A/G	0.05	2.21 (1.52-3.19)	7.33E-05	0.06	1.15 (0.73-1.77)	0.39	1.69 (1.27-2.25)	2.90E-04
rs1552126	14q32.2	-	97063843	C/T	0.42	0.69 (0.57-0.82)	8.46E-05	0.43	0.90 (0.65-1.24)	0.81	0.73 (0.62-0.86)	1.13E-04

<sup>a</sup> Per allele odds ratios (OR) with 95% confidence intervals (CI) and per allele *P*-values.

<sup>b</sup> SNPs with *P*-values < 0.05 in association with risk of follicular lymphoma in Stage 2 (SF1 study).

MAF: minor allele frequency, SCALE: Scandinavian lymphoma etiology, SF: San Francisco